FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Hart Daniel Ryan
2. Issuer Name and Ticker or Trading Symbol

Avid Bioservices, Inc. [ CDMO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Financial Officer
(Last)          (First)          (Middle)

2642 MICHELLE DRIVE., SUITE 200
3. Date of Earliest Transaction (MM/DD/YYYY)

10/31/2019
(Street)

TUSTIN, CA 92780
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  10/31/2019    J(1)    2693  A $3.944  4982  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
(1)  Shares purchased under the issuer's Employee Stock Purchase Plan ("ESPP") for the ESPP offering period May 1, 2019 through October 31, 2019. In accordance with the ESPP, these shares were purchased at a price equal to 85% of the closing price of the issuer's common stock on May 1, 2019.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Hart Daniel Ryan
2642 MICHELLE DRIVE., SUITE 200
TUSTIN, CA 92780


Chief Financial Officer

Signatures
/s/ Daniel R. Hart 10/31/2019
**Signature of Reporting Person Date


Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Avid Bioservices Charts.
Avid Bioservices (NASDAQ:CDMOP)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Avid Bioservices Charts.

News Avid Bioservices, Inc.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
Dienstag 2 Juli 2024 (2 Wochen vor) • GlobeNewswire Inc.
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
Montag 1 Juli 2024 (2 Wochen vor) • GlobeNewswire Inc.
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
Donnerstag 23 Mai 2024 (2 Monate vor) • GlobeNewswire Inc.
Avid Bioservices to Participate at Upcoming Investor Conferences
Dienstag 7 Mai 2024 (2 Monate vor) • GlobeNewswire Inc.
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
Mittwoch 24 April 2024 (3 Monate vor) • GlobeNewswire Inc.
Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q
Mittwoch 20 März 2024 (4 Monate vor) • GlobeNewswire Inc.
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
Donnerstag 7 März 2024 (4 Monate vor) • GlobeNewswire Inc.
Avid Bioservices Announces Proposed Private Placement of Convertible Notes
Mittwoch 6 März 2024 (4 Monate vor) • GlobeNewswire Inc.
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
Mittwoch 6 März 2024 (4 Monate vor) • GlobeNewswire Inc.
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2023
Donnerstag 7 Dezember 2023 (7 Monate vor) • GlobeNewswire Inc.
Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023
Donnerstag 30 November 2023 (8 Monate vor) • GlobeNewswire Inc.
Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs
Mittwoch 8 November 2023 (8 Monate vor) • GlobeNewswire Inc.